-
On February 17, 2026, Amgen Inc. issued US$1.00 billion of 4.200% Senior Notes due 2031, US$1.75 billion of 4.850% Senior Notes due 2036, US$500 million of 5.500% Senior Notes due 2046 and US$750 million of 5.650% Senior Notes due 2056, raising about US$3.96 billion in net proceeds under its existing shelf registration.
-
The new multi-decade bond maturities and change-of-control protection highlight how Amgen is structuring its capital stack to support long-term investment plans while balancing creditor protections.
-
Next, we’ll examine how this large-scale debt issuance and extended maturities interact with Amgen’s existing investment narrative and risk profile.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
To own Amgen today, I think you need to believe its obesity, cardiovascular, and oncology pipelines can offset mounting biosimilar pressure and pricing scrutiny, while its dividend and cash generation stay resilient. The new US$3.96 billion in long-dated senior notes does not materially change that near term, but it does slightly raise balance sheet risk if R&D or large trials underperform expectations.
Against this backdrop, the recent 2026 revenue guidance of US$37.0 billion to US$38.4 billion is the key reference point when thinking about how this financing might support, or strain, Amgen’s ability to fund late-stage assets like MariTide and its BiTE oncology programs without overly compressing margins or crowding out future shareholder returns.
Yet behind the optimism, investors should be aware that growing leverage could magnify the impact of any pipeline setback or pricing shock on…
Read the full narrative on Amgen (it’s free!)
Amgen’s narrative projects $37.4 billion in revenue and $8.2 billion in earnings by 2028. This requires 2.3% yearly revenue growth and about a $1.6 billion earnings increase from $6.6 billion today.
Uncover how Amgen’s forecasts yield a $327.74 fair value, a 16% downside to its current price.
Some of the most optimistic analysts were already modeling revenue of about US$42.8 billion and earnings near US$13.3 billion, so you should expect their views on debt funded growth and acquisition risk to shift as this latest bond issuance is digested and compare that more bullish story with more cautious scenarios.